22nd Century Group Inc (XXII)

[nonameface13]

Cannabis stocks fall after FDA hearing on CBD finds conflicting views of substance

https://www.marketwatch.com/story/cannabis-stocks-fall-after-fda-hearing-on-cbd-finds-conflicting-views-of-substance-2019-06-03

The hearing “highlighted the messy state of the industry, with widespread use of CBD products with minimal standardization, evidence for benefit and understanding of safety profile,” said Evercore ISI analysts led by Josh Schimmer in a note to clients.

...profiles, where have I seen this before:
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today that the Company has entered into a worldwide strategic research and development agreement with KeyGene, www.keygene.com, a global leader in plant research involving high-value genetic traits and increased crop yields. This exclusive, worldwide collaboration will focus on developing hemp/cannabis plants with exceptional cannabinoid profiles for medical and therapeutic use among other applications.

https://marijuanastocks.com/xxii-announces-exclusive-worldwide-agreement-with-keygene/